Serum concentrations and gene expression of sirtuin 1 in healthy and slightly overweight subjects after caloric restriction or resveratrol supplementation: A randomized trial

International Journal of Cardiology

Volumn 227, Issue , 2017, Pages 788-794

  Mansur, Antonio P ^a   Roggerio, Alessandra ^a   Goes, Marisa F S ^a   Avakian, Solange D ^a   Leal, Dalila P ^a   Maranhão, Raul C ^a   Strunz, Célia M C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Caloric restriction; Gene expression; Human population; Resveratrol; Sirtuin 1

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; RESVERATROL; RNA; SIRTUIN 1; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER; LIPID; SIRT1 PROTEIN, HUMAN; STILBENE DERIVATIVE;

ABDOMINAL CIRCUMFERENCE; ADULT; AGED; ARTICLE; BLOOD CLOTTING; CALORIC RESTRICTION; CLINICAL FEATURE; CLOT STRENGTH; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DISEASE SEVERITY; FEMALE; GENE EXPRESSION PROFILING; HEMATOLOGICAL PARAMETERS; HUMAN; LIPID ANALYSIS; MALE; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SIRT1 GENE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; TREATMENT DURATION; WAIST CIRCUMFERENCE; BIOSYNTHESIS; BLOOD; DIET THERAPY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED;

BIOMARKERS; CALORIC RESTRICTION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIPIDS; MALE; MIDDLE AGED; OVERWEIGHT; PROSPECTIVE STUDIES; SIRTUIN 1; STILBENES;

EID: 85004191431     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.10.058     Document Type: Article

References (48)

1. [1] Guarente, L., Sirtuins, aging, and medicine. N. Engl. J. Med. 364 (2011), 2235–2244.
2. [2] Kanfi, Y., Naiman, S., Amir, G., et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature 483 (2012), 218–221.
3. [3] Albani, D., Ateri, E., Mazzuco, S., et al. Modulation of human longevity by SIRT3 single nucleotide polymorphisms in the prospective study “Treviso Longeva (TRELONG)”. Age (Dordr.) 36 (2014), 469–478.
4. [4] Frye, R.A., Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 273 (2000), 793–798.
5. [5] Imai, S., The NAD, World: a new systemic regulatory network for metabolism and aging – Sirt1, systemic NAD biosynthesis, and their importance. Cell Biochem. Biophys. 53 (2009), 65–74.
6. [6] Ristow, M., Zarse, K., How increased oxidative stress promotes longevity and metabolic health: The concept of mitochondrial hormesis (mitohormesis). Exp. Gerontol. 45 (2010), 410–418.
7. [7] Saunders, L.R., Verdin, E., Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26 (2007), 5489–5504.
8. [8] Haigis, M.C., Sinclair, D.A., Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 5 (2010), 253–295.
9. [9] Nemoto, S., Fergusson, M.M., Finkel, T., Nutrient availability regulates SIRT1 through a forkhead dependent pathway. Science 306 (2004), 2105–2108.
10. [10] Lagouge, M., Argmann, C., Gerhart-Hines, Z., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 127 (2006), 1109–1122.
11. [11] Guarente, L., Calorie restriction and sirtuins revisited. Genes Dev. 27 (2013), 2072–2085.
12. [12] Poulsen, M.M., Jørgensen, J.O., Jessen, N., Richelsen, B., Pedersen, S.B., Resveratrol in metabolic health: an overview of the current evidence and perspectives. Ann. N. Y. Acad. Sci. 1290 (2013), 74–82.
13. [13] Stünkel, W., Campbell, R.M., Sirtuin 1 (SIRT1): the misunderstood HDAC. J. Biomol. Screen. 16 (2011), 1153–1169.
14. [14] Michan, S., Sinclair, D., Sirtuins in mammals: insights into their biological function. Biochem. J. 404 (2007), 1–13.
15. [15] Potente, M., Ghaeni, L., Baldessari, D., et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev. 21 (2007), 2644–2658.
16. [16] Gorenne, I., Kumar, S., Gray, K., et al. Vascular smooth muscle cell sirtuin 1 protects against DNA damage and inhibits atherosclerosis. Circulation 127 (2013), 386–396.
17. [17] Mattagajasingh, I., Kim, C.S., Naqvi, A., et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 14855–14860.
18. [18] Li, X., Zhang, S., Blander, G., Tse, J.G., Krieger, M., Guarente, L., SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 28 (2007), 91–106.
19. [19] Sun, C., Zhang, F., Ge, X., et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 6 (2007), 307–319.
20. [20] Potente, M., Dimmeler, S., Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle 7 (2008), 2117–2122.
21. [21] Mariani, S., Fiore, D., Basciani, S., et al. Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients. Endocrine 49 (2015), 711–716.
22. [22] Mariani, S., Fiore, D., Persichetti, A., et al. Circulating SIRT1 increases after intragastric balloon fat loss in obese patients. Obes. Surg. 26 (2016), 1215–1220.
23. [23] Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
24. [24] Born, G.V.R., Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194 (1962), 927–929.
25. [25] Dansinger, M.L., Gleason, J.A., Griffith, J.L., Selker, H.P., Schaefer, E.J., Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 293 (2005), 43–53.
26. [26] Weindruch, R., Walford, R.L., The Retardation of Aging and Disease by Dietary Restriction. 1988, Charles C Thomas Publisher, Springfield, Illinois, 436.
27. [27] Heilbronn, L.K., de Jonge, L., Frisard, M.I., et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA 295 (2006), 1539–1548.
28. [28] Kitada, M., Kume, S., Takeda-Watanabe, A., Tsuda, S., Kanasaki, K., Koya, D., Calorie restriction in overweight males ameliorates obesity-related metabolic alterations and cellular adaptations through anti-aging effects, possibly including AMPK and SIRT1 activation. Biochim. Biophys. Acta 2013 (1830), 4820–4827.
29. [29] Fontana, L., Meyer, T.E., Klein, S., Holloszy, J.O., Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 6659–6663.
30. [30] Fontana, L., Villareal, D.T., Weiss, E.P., et al. Calorie restriction or exercise: effects on coronary heart disease risk factors. A randomized, controlled trial. Am. J. Physiol. Endocrinol. Metab. 293 (2007), E197–E202.
31. [31] Choi, K.M., Han, K.A., Ahn, H.J., et al. The effects of caloric restriction on fetuin-A and cardiovascular risk factors in rats and humans: a randomized controlled trial. Clin. Endocrinol. 79 (2013), 356–363.
32. [32] Kanfi, Y., Peshti, V., Gozlan, Y.M., et al. Regulation of SIRT1 protein levels by nutrient availability. FEBS Lett. 582 (2008), 2417–2423.
33. [33] Davì, G., Guagnano, M.T., Ciabattoni, G., Basili, S., Falco, A., Marinopiccoli, M., Nutini, M., Sensi, S., Patrono, C., Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 288 (2002), 2008–2014.
34. [34] Moscardó, A., Vallés, J., Latorre, A., Jover, R., Santos, M.T., The histone deacetylase sirtuin 2 is a new player in the regulation of platelet function. J. Thromb. Haemost. 13 (2015), 1335–1344.
35. [35] van der Made, S.M., Plat, J., Mensink, R.P., Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial. PLoS One, 10(3), 2015, e0118393 10.1371/journal.pone.0118393.
36. [36] Zamora-Ros, R., Urpi-Sarda, M., Lamuela-Raventós, R.M., et al. High urinary levels of resveratrol metabolites are associated with a reduction in the prevalence of cardiovascular risk factors in high-risk patients. Pharmacol. Res. 65 (2012), 615–620.
37. [37] Tomé-Carneiro, J., Gonzálvez, M., Larrosa, M., et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am. J. Cardiol. 110 (2012), 356–363.
38. [38] Tomé-Carneiro, J., Gonzálvez, M., Larrosa, M., et al. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol. Nutr. Food Res. 56 (2012), 810–821.
39. [39] Lasa, A., Schweiger, M., Kotzbeck, P., et al. Resveratrol regulates lipolysis via adipose triglyceride lipase. J. Nutr. Biochem. 23 (2012), 379–384.
40. [40] Timmers, S., Konings, E., Bilet, L., et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 14 (2011), 612–622.
41. [41] Poulsen, M.M., Vestergaard, P.F., Clasen, B.F., et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 62 (2013), 1186–1195.
42. [42] Liu, K., Zhou, R., Wang, B., Mi, M.T., Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am. J. Clin. Nutr. 99 (2014), 1510–1519.
43. [43] Pace-Asciak, C.R., Rounova, O., Hahn, S.E., Diamandis, E.P., Goldberg, D.M., Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin. Chim. Acta 246 (1996), 163–182.
44. [44] Wang, Z., Huang, Y., Zou, J., Cao, K., Xu, Y., Wu, J.M., Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int. J. Mol. Med. 9 (2002), 77–79.
45. [45] Stef, G., Csiszar, A., Lerea, K., Ungvari, Z., Veress, G., Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance. J. Cardiovasc. Pharmacol. 48 (2006), 1–5.
46. [46] Vitaglione, P., Sforza, S., Galaverna, G., et al. Bioavailability of trans-resveratrol from red wine in humans. Mol. Nutr. Food Res. 49 (2005), 495–504.
47. [47] Lam, Y.Y., Peterson, C.M., Ravussin, E., Resveratrol vs. calorie restriction: data from rodents to humans. Exp. Gerontol. 48 (2013), 1018–1024.
48. [48] Mohar, D.S., Malik, S., The sirtuin system: the holy grail of resveratrol?. J. Clin. Exp. Cardiol., 3(11), 2012 (pii: 216).